Arcutis Biotherapeutics, Inc. ARQT
Set alert
31.26 USD -0.81 -2.53%
At close
31.00 -0.26 -0.83%
Pre-market · Nov 3, 7:32 AM ET
31.20 Day range 32.24
19.30 52-week range 33.30
- YTD
- +7.64%
- 1 year
- +23.51%
- Open
- 32.07
- Prev close
- 32.07
- Mkt cap
- 3.93B
- Vol
- 1.51M
- Avg vol
- 2.51M
- EPS
- 0.22
- P/E
- 142.09
- Div yield
- 0.00%
More statistics
- Low
- 31.20
- High
- 32.24
- Forward P/E
- 23.34
- Beta
- 1.63
- Short ratio
- 6.13
- Inst. own
- 108.57%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 26.66
- 200-d avg
- 25.25
- 1y target
- 39.13
MAX chart
Events in this range
- Aug 6, 2025Earnings: -0.13; estimate -0.18; surprise 27.78%
- Oct 28, 2025Earnings: 0.06; estimate -0.1; surprise 160%
- Feb 25, 2026Earnings: 0.13; estimate 0.03; surprise 333.33%
- May 6, 2026Earnings: -0.09; estimate -0.02; surprise -350%
- May 7, 2026Rating: Needham · Buy → Buy
- Aug 5, 2026Earnings: 0.11; estimate 0.05508; surprise 99.71%
- Aug 6, 2026Rating: Needham · Buy → Buy
- Aug 6, 2026Rating: Guggenheim · Buy → Buy
- Aug 6, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 15, 2026Rating: Cantor Fitzgerald · — → Overweight
- Oct 19, 2026Rating: Guggenheim · Buy → Buy
- Nov 4, 2026Earnings: —; estimate 0.18; surprise —%
Signals (132)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bullish | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 24, 2026 | 2 months ago |
| SMA: Bearish | Aug 3, 2026 | 3 months ago |
| SMA: Bullish | Jun 15, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 23, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| SMA: Bearish | Jan 5, 2026 | 10 months ago |
| RSI: Overbought | Dec 22, 2025 | 10 months ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
Newest 20 of 132.
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.13 +25.2% upside
Now 31.26
- Target (low)
- 34.00
- Target (mean)
- 39.13
- Target (high)
- 48.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 8
- 1 month ago 7
- 2 months ago 8
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.16833 | 0.10 – 0.20 | 0.06 | +180.6% | 142.59M | +43.7% | 6 |
| Next quarter | 0.23167 | 0.03 – 0.39 | 0.13 | +78.2% | 160.67M | +24.1% | 6 |
| Current year | 0.425 | 0.20 – 0.62 | -0.13 | +426.9% | 538.56M | +43.2% | 6 |
| Next year | 1.34 | 0.80 – 2.08 | 0.425 | +214.9% | 695.69M | +29.2% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 15, 2026 | Cantor Fitzgerald | Initiated | — | Overweight |
| Aug 6, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Aug 6, 2026 | Needham | Maintained | Buy | Buy |
| May 7, 2026 | Needham | Reiterated | Buy | Buy |
| Mar 2, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Feb 27, 2026 | Guggenheim | Maintained | Buy | Buy |
| Feb 26, 2026 | TD Cowen | Maintained | Buy | Buy |
| Feb 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 26, 2026 | Needham | Maintained | Buy | Buy |
| Jan 26, 2026 | Needham | Maintained | Buy | Buy |
| Nov 28, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Oct 30, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Oct 28, 2025 | Needham | Maintained | Buy | Buy |
| Aug 7, 2025 | Needham | Maintained | Buy | Buy |
| Jul 25, 2025 | Goldman Sachs | Initiated | — | Neutral |
| May 23, 2025 | Needham | Reiterated | Buy | Buy |
| Apr 9, 2025 | Needham | Reiterated | Buy | Buy |
| Apr 3, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Apr 3, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 3, 2025 | Needham | Reiterated | Buy | Buy |
| Mar 11, 2025 | Jefferies | Maintained | Buy | Buy |
| Feb 27, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Feb 26, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 26, 2025 | Mizuho | Maintained | Outperform | Outperform |
| Feb 26, 2025 | Needham | Reiterated | Buy | Buy |
| Feb 24, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Feb 10, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Jan 13, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |